What we do Smruthi Organics Ltd manufactures Active Pharmaceutical Ingredients (APIs) for anti-diabetic, anti-hypertension, and anti-infective therapies, serving global markets including Asia, Americas, and Africa. |
Founded in 1,989 |
Market share Established presence in Indian and international pharmaceutical API markets with steady revenue and global client base. |
Problem solved Provides high-quality bulk drugs to address chronic diseases and infections, supporting affordable healthcare globally. |
Top clients or who we serve Serves pharmaceutical companies across Asia, Americas, Africa; B2B model focusing on global API supply and emerging formulation segment. |
Key management E. Purushotham, Chairman & Managing Director; E. Swapnil, Joint Managing Director & CFO. |
Our journey and innovations Started with bulk drugs in 1989, expanded product range in 1990s, recent launch of new formulation brands including ENERLIN and SOLSITA. |
Where we operate Domestic operations in India with exports to the UK and various countries in Asia, Americas, and Africa. |
Top products or what we offer API manufacturing for bulk drugs like diloxanide furoate, sulphadiazine, ciprofloxacin, ranitidine HCl; finished dosage formulations launched recently. |
Top brands ENERLIN - pain relief; SOLSITA - anti-histamine; TRANVIA P and YAMONT LC also launched in 2023-24. |
Raw materials needed Active pharmaceutical raw materials for producing APIs including chemical intermediates like furoic acid. |
Raw materials supplier Information not specified; likely sourced from chemical suppliers in India and internationally. |
Recurring vs cyclical contribution Revenue primarily recurring from API sales; formulation segment is emerging with mixed cyclicality. |
Our industry position Steady mid-sized player in pharmaceutical bulk drugs with growing formulation presence and diversified export markets. |
Financial highlights FY 24-25 revenue approximately Rs 126 crore; profit around Rs 3.56 crore; slight decrease from previous year, stable performance. |
Geographical revenue split About 46% revenue from India and 54% from outside India, indicating strong export orientation. |
Order book - |
Whats driving growth Growth driven by expanding API exports, new formulation launches, and continuous capacity enhancements. |
Our future plans Focus on expanding finished dosage formulations segment and increasing capacity utilization in API manufacturing. |
Our green promise - |
Our people and values Employs around 267 staff, emphasizing safety and harmonious industrial relations with continuous training. |
Key challenges ahead Managing cost pressures, finance costs impact margins, and competitive pharmaceutical API market risks. |
Interesting facts Operational since 1989 with two manufacturing plants in Solapur and recent diversification into formulations. |
Risks and strategy Faces market competition and regulatory risks; mitigated by diversification and adherence to quality norms. |
